Resource Summary Report

Generated by RRID on Jul 28, 2026

Ultra-LEAF(TM) Purified anti-human CD28

RRID:AB_11148949
Type: Antibody

Proper Citation

BioLegend Cat# 302934, RRID:AB_11148949

Antibody Information

URL: http://antibodyregistry.org/AB_11148949

Proper Citation: BioLegend Cat# 302934, RRID:AB_11148949

Target Antigen: CD28

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: FC, IHC-F, Costim, FA

Antibody Name: Ultra-LEAF(TM) Purified anti-human CD28

Description: This monoclonal targets CD28

Target Organism: cynomolgus, rhesus, human

Clone ID: Clone CD28.2

Antibody ID: AB_11148949

Vendor: BioLegend

Catalog Number: 302934

Alternative Catalog Numbers: 302943, 302933, 302944, 302959, 302960

Record Creation Time: 20250820T040744+0000

Record Last Update: 20250820T180740+0000

Ratings and Alerts

No rating or validation information has been found for Ultra-LEAF(TM) Purified anti-human CD28.

No alerts have been found for Ultra-LEAF(TM) Purified anti-human CD28.

Data and Source Information

Source: Antibody Registry

Usage and Citation Metrics

We found 44 mentions in open access literature.

Listed below are recent publications. The full list is available at RRID .

Rainwater RR, et al. (2026) DNA-PKcs controls the cytotoxic T cell response to cancer and transplant allograft through regulating LAT-dependent signaling. Cell reports, 45(1), 116796.

Jones RD, et al. (2026) Tunable differentiation of human CD4+ and CD8+ T cells from pluripotent stem cells. Cell stem cell, 33(1), 73.

Chimote AA, et al. (2025) Potassium channels mediate the inhibitory effect of exosomes on anti-tumor immunity in head and neck cancer. bioRxiv : the preprint server for biology.

Ma K, et al. (2025) Succinate preserves CD8+ T cell fitness to augment antitumor immunity. Immunity.

Koliesnik I, et al. (2025) An IL-12 partial agonist sustains intratumoral lymphocyte activation and detoxifies systemic IL-12 therapy. Cell reports, 45(1), 116757.

Li J, et al. (2025) Monocyte/macrophage-derived interleukin-15 mediates the pro-inflammatory phenotype of CD226+ B cells in type 1 diabetes. EBioMedicine, 120, 105946.

Xiao Z, et al. (2025) Engineered T cells stimulate dendritic cell recruitment and antigen spreading for potent anti-tumor immunity. Cell reports. Medicine, 6(9), 102307.

Qiu Y, et al. (2025) Mannose metabolism reshapes T cell differentiation to enhance anti-tumor immunity. Cancer cell, 43(1), 103.

Li T, et al. (2025) Non-canonical PRC1.1 licenses transcriptional response to enable Treg plasticity in immune adaptation. Molecular cell, 85(13), 2517.

Xing R, et al. (2025) Enhanced formation of tertiary lymphoid structures shapes the anti-tumor microenvironment in hepatocellular carcinoma after FOLFOX-HAIC therapy. Cell reports. Medicine, 6(9), 102298.

Wong YC, et al. (2025) An open-label study on the safety and immunogenicity of a PD-1-enhanced DNA vaccine used as a T cell booster for COVID-19. EBioMedicine, 115,

105699.

von Locquenghien M, et al. (2025) Macrophage-targeted immunocytokine leverages myeloid, T, and NK cell synergy for cancer immunotherapy. Cell, 188(25), 7099.

Yu S, et al. (2025) Caveolin-1/PPAR? axis suppresses T follicular helper cell response in primary Sjögren disease. Cell reports, 44(8), 116156.

Zhao Y, et al. (2024) Personalized drug screening using patient-derived organoid and its clinical relevance in gastric cancer. Cell reports. Medicine, 5(7), 101627.

Cong J, et al. (2024) Bile acids modified by the intestinal microbiota promote colorectal cancer growth by suppressing CD8+ T cell effector functions. Immunity.

Kong XX, et al. (2024) Circulation immune cell landscape in canonical pathogenesis of colorectal adenocarcinoma by CyTOF analysis. iScience, 27(3), 109229.

Jia D, et al. (2024) Microbial metabolite enhances immunotherapy efficacy by modulating T cell stemness in pan-cancer. Cell, 187(7), 1651.

Dong B, et al. (2024) NK Receptor Signaling Lowers TCR Activation Threshold, Enhancing Selective Recognition of Cancer Cells by TAA-Specific CTLs. Cancer immunology research, 12(10), 1421.

Pettinella F, et al. (2024) Surface CD52, CD84, and PTGER2 mark mature PMN-MDSCs from cancer patients and G-CSF-treated donors. Cell reports. Medicine, 5(2), 101380.

Jaeger-Ruckstuhl CA, et al. (2024) Signaling via a CD27-TRAF2-SHP-1 axis during naive T cell activation promotes memory-associated gene regulatory networks. Immunity, 57(2), 287.